Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Exploratory Phase II Study of the Safety and Immunogenicity of Repeated "rhC1INH" Administration of 50 U/Kg in Patients With Hereditary C1 Inhibitor Deficiency ("HAE")

NCT00851409 is registered in ClinicalTrials.gov with Pharming Technologies B.V. as lead sponsor.

NCT NCT00851409
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00851409 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Exploratory Phase II Study of the Safety and Immunogenicity of Repeated "rhC1INH" Administration of 50 U/Kg in Patients With Hereditary C1 Inhibitor Deficiency ("HAE")
Lead sponsor
Pharming Technologies B.V.
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2009
Completion date
April 30, 2010
Enrollment
25 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

genetic disorders, hereditary angioedema